Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin

P. M. Busse, J. R. Clark, C. J. Beard, A. I. Dreyfuss, J. W. Lucarini, R. Rossi, D. Casey, C. M. Norris

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A phase II clinical trial was initiated in 1987 to evaluate a new induction regimen of cis-platinum, 5-fluorouracil, and leucovorin (PFL) for patients with stages III-IV squamous cell carcinoma of the head and neck. Ninety patients were treated and followed for a median duration of 18 months. The median age was 55 and 87% of the patients had stage IV disease. The rates of complete and overall clinical response following three cycles of PFL were 57% and 80%, respectively; the rate of complete response at the primary site was 72%. Eighty-four percent of patients were treated to the primary site with radiation alone (median dose 68 Gy in daily 1.8-Gy fractions) irrespective of the location of the primary site or initial T-stage. The acute tolerance to full-course radiation following PFL was acceptable. The actuarial rate of primary site control for patients treated with radiation was 67% at 36 months. An important prognostic indicator for primary site control was a complete clinical response to induction PFL. For patients who achieved a complete response, radiation or surgery followed by radiation controlled primary site disease equally well at 70%. Patients with a partial response did less well. For these patients, surgery and radiation appeared slightly better than radiation alone.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalHead and Neck
Volume15
Issue number5
StatePublished - 1993

Fingerprint

Induction Chemotherapy
Leucovorin
Fluorouracil
Cisplatin
Radiation
Platinum
Phase II Clinical Trials

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Busse, P. M., Clark, J. R., Beard, C. J., Dreyfuss, A. I., Lucarini, J. W., Rossi, R., ... Norris, C. M. (1993). Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin. Head and Neck, 15(5), 413-418.

Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin. / Busse, P. M.; Clark, J. R.; Beard, C. J.; Dreyfuss, A. I.; Lucarini, J. W.; Rossi, R.; Casey, D.; Norris, C. M.

In: Head and Neck, Vol. 15, No. 5, 1993, p. 413-418.

Research output: Contribution to journalArticle

Busse, PM, Clark, JR, Beard, CJ, Dreyfuss, AI, Lucarini, JW, Rossi, R, Casey, D & Norris, CM 1993, 'Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin', Head and Neck, vol. 15, no. 5, pp. 413-418.
Busse, P. M. ; Clark, J. R. ; Beard, C. J. ; Dreyfuss, A. I. ; Lucarini, J. W. ; Rossi, R. ; Casey, D. ; Norris, C. M. / Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin. In: Head and Neck. 1993 ; Vol. 15, No. 5. pp. 413-418.
@article{1c4e1d8407b74c029c33afc4705c526c,
title = "Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin",
abstract = "A phase II clinical trial was initiated in 1987 to evaluate a new induction regimen of cis-platinum, 5-fluorouracil, and leucovorin (PFL) for patients with stages III-IV squamous cell carcinoma of the head and neck. Ninety patients were treated and followed for a median duration of 18 months. The median age was 55 and 87{\%} of the patients had stage IV disease. The rates of complete and overall clinical response following three cycles of PFL were 57{\%} and 80{\%}, respectively; the rate of complete response at the primary site was 72{\%}. Eighty-four percent of patients were treated to the primary site with radiation alone (median dose 68 Gy in daily 1.8-Gy fractions) irrespective of the location of the primary site or initial T-stage. The acute tolerance to full-course radiation following PFL was acceptable. The actuarial rate of primary site control for patients treated with radiation was 67{\%} at 36 months. An important prognostic indicator for primary site control was a complete clinical response to induction PFL. For patients who achieved a complete response, radiation or surgery followed by radiation controlled primary site disease equally well at 70{\%}. Patients with a partial response did less well. For these patients, surgery and radiation appeared slightly better than radiation alone.",
author = "Busse, {P. M.} and Clark, {J. R.} and Beard, {C. J.} and Dreyfuss, {A. I.} and Lucarini, {J. W.} and R. Rossi and D. Casey and Norris, {C. M.}",
year = "1993",
language = "English (US)",
volume = "15",
pages = "413--418",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Primary site management following induction chemotherapy with cis- platinum, 5-fluorouracil, and leucovorin

AU - Busse, P. M.

AU - Clark, J. R.

AU - Beard, C. J.

AU - Dreyfuss, A. I.

AU - Lucarini, J. W.

AU - Rossi, R.

AU - Casey, D.

AU - Norris, C. M.

PY - 1993

Y1 - 1993

N2 - A phase II clinical trial was initiated in 1987 to evaluate a new induction regimen of cis-platinum, 5-fluorouracil, and leucovorin (PFL) for patients with stages III-IV squamous cell carcinoma of the head and neck. Ninety patients were treated and followed for a median duration of 18 months. The median age was 55 and 87% of the patients had stage IV disease. The rates of complete and overall clinical response following three cycles of PFL were 57% and 80%, respectively; the rate of complete response at the primary site was 72%. Eighty-four percent of patients were treated to the primary site with radiation alone (median dose 68 Gy in daily 1.8-Gy fractions) irrespective of the location of the primary site or initial T-stage. The acute tolerance to full-course radiation following PFL was acceptable. The actuarial rate of primary site control for patients treated with radiation was 67% at 36 months. An important prognostic indicator for primary site control was a complete clinical response to induction PFL. For patients who achieved a complete response, radiation or surgery followed by radiation controlled primary site disease equally well at 70%. Patients with a partial response did less well. For these patients, surgery and radiation appeared slightly better than radiation alone.

AB - A phase II clinical trial was initiated in 1987 to evaluate a new induction regimen of cis-platinum, 5-fluorouracil, and leucovorin (PFL) for patients with stages III-IV squamous cell carcinoma of the head and neck. Ninety patients were treated and followed for a median duration of 18 months. The median age was 55 and 87% of the patients had stage IV disease. The rates of complete and overall clinical response following three cycles of PFL were 57% and 80%, respectively; the rate of complete response at the primary site was 72%. Eighty-four percent of patients were treated to the primary site with radiation alone (median dose 68 Gy in daily 1.8-Gy fractions) irrespective of the location of the primary site or initial T-stage. The acute tolerance to full-course radiation following PFL was acceptable. The actuarial rate of primary site control for patients treated with radiation was 67% at 36 months. An important prognostic indicator for primary site control was a complete clinical response to induction PFL. For patients who achieved a complete response, radiation or surgery followed by radiation controlled primary site disease equally well at 70%. Patients with a partial response did less well. For these patients, surgery and radiation appeared slightly better than radiation alone.

UR - http://www.scopus.com/inward/record.url?scp=0027214058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027214058&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 413

EP - 418

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 5

ER -